Which has better valuation and earnings, LONA or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$4.21 N/A Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A

Is LONA or TTRX more profitable?

Turn Therapeutics' return on equity of -230.84% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Turn Therapeutics N/A -230.84% -53.19%

Which has preferable earnings and valuation, LONA or NMRA?

Athira Pharma is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$4.21 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A

Is LONA or NMRA more profitable?

Neumora Therapeutics' return on equity of -242.28% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Neumora Therapeutics N/A -242.28% -131.32%

Does the media refer more to LONA or NMRA?

In the previous week, Athira Pharma had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for Neumora Therapeutics. Athira Pharma's average media sentiment score of 0.00 equaled Neumora Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LONA or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Zentalis Pharmaceuticals N/A -70.18% -51.46%

Does the media refer more to LONA or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Athira Pharma. MarketBeat recorded 5 mentions for Zentalis Pharmaceuticals and 2 mentions for Athira Pharma. Zentalis Pharmaceuticals' average media sentiment score of 0.71 beat Athira Pharma's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer LONA or ACB?

Athira Pharma currently has a consensus target price of $17.33, indicating a potential upside of 125.11%. Given Athira Pharma's higher possible upside, equities analysts plainly believe Athira Pharma is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media refer more to LONA or ACB?

In the previous week, Aurora Cannabis had 4 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for Aurora Cannabis and 2 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Aurora Cannabis' score of -0.68 indicating that Athira Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurora Cannabis 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Negative

Which has better valuation and earnings, LONA or NERV?

Athira Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$4.21 N/A Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A

Is LONA or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Minerva Neurosciences N/A N/A -31.72%

Does the media favor LONA or NERV?

In the previous week, Athira Pharma had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for Minerva Neurosciences. Athira Pharma's average media sentiment score of 0.00 equaled Minerva Neurosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Athira Pharma (LONA) Competitors

$7.70 +0.03 (+0.39%)

As of 09/3/2026 03:45 PM Eastern

Compare

LONA vs. TTRX, NMRA, ZNTL, ACB, and NERV

Should you buy Athira Pharma stock or one of its competitors? Athira Pharma's main competitors and comparable companies include Turn Therapeutics (TTRX), Neumora Therapeutics (NMRA), Zentalis Pharmaceuticals (ZNTL), Aurora Cannabis (ACB), and Minerva Neurosciences (NERV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Athira Pharma compare to Turn Therapeutics?

Athira Pharma (NASDAQ:LONA) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Turn Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

57.1% of Athira Pharma shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Athira Pharma had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 2 mentions for Athira Pharma and 0 mentions for Turn Therapeutics. Athira Pharma's average media sentiment score of 0.00 equaled Turn Therapeutics'average media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Turn Therapeutics	Neutral

Athira Pharma presently has a consensus price target of $17.33, indicating a potential upside of 125.11%. Turn Therapeutics has a consensus price target of $8.00, indicating a potential downside of 20.56%. Given Athira Pharma's higher probable upside, equities research analysts plainly believe Athira Pharma is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Turn Therapeutics' return on equity of -230.84% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Turn Therapeutics	N/A	-230.84%	-53.19%

Summary

Athira Pharma beats Turn Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Athira Pharma compare to Neumora Therapeutics?

Athira Pharma (NASDAQ:LONA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Athira Pharma is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Athira Pharma has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market.

Athira Pharma currently has a consensus price target of $17.33, indicating a potential upside of 125.11%. Neumora Therapeutics has a consensus price target of $6.57, indicating a potential upside of 386.77%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Athira Pharma had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for Neumora Therapeutics. Athira Pharma's average media sentiment score of 0.00 equaled Neumora Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neumora Therapeutics' return on equity of -242.28% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Neumora Therapeutics	N/A	-242.28%	-131.32%

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Neumora Therapeutics beats Athira Pharma on 10 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Athira Pharma (NASDAQ:LONA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Zentalis Pharmaceuticals' return on equity of -70.18% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Athira Pharma has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Zentalis Pharmaceuticals	$67.43M	4.37	-$137.06M	-$1.95	N/A

57.1% of Athira Pharma shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Athira Pharma has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Athira Pharma currently has a consensus target price of $17.33, suggesting a potential upside of 125.11%. Zentalis Pharmaceuticals has a consensus target price of $6.75, suggesting a potential upside of 64.23%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Athira Pharma. MarketBeat recorded 5 mentions for Zentalis Pharmaceuticals and 2 mentions for Athira Pharma. Zentalis Pharmaceuticals' average media sentiment score of 0.71 beat Athira Pharma's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Athira Pharma beats Zentalis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to Aurora Cannabis?

Athira Pharma (NASDAQ:LONA) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Athira Pharma currently has a consensus target price of $17.33, indicating a potential upside of 125.11%. Given Athira Pharma's higher possible upside, equities analysts plainly believe Athira Pharma is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Athira Pharma has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aurora Cannabis had 4 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for Aurora Cannabis and 2 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Aurora Cannabis' score of -0.68 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurora Cannabis	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Negative

Athira Pharma has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Aurora Cannabis	-32.26%	4.37%	3.45%

Aurora Cannabis has higher revenue and earnings than Athira Pharma. Aurora Cannabis is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Aurora Cannabis	$247.82M	1.02	-$88.13M	-$1.41	N/A

Summary

Athira Pharma beats Aurora Cannabis on 8 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Minerva Neurosciences?

Athira Pharma (NASDAQ:LONA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Athira Pharma currently has a consensus price target of $17.33, suggesting a potential upside of 125.11%. Minerva Neurosciences has a consensus price target of $10.33, suggesting a potential upside of 120.33%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Athira Pharma had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for Minerva Neurosciences. Athira Pharma's average media sentiment score of 0.00 equaled Minerva Neurosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Athira Pharma has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market.

Athira Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

Minerva Neurosciences' return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Minerva Neurosciences	N/A	N/A	-31.72%

Summary

Athira Pharma beats Minerva Neurosciences on 9 of the 12 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LONA vs. The Competition

Export

Metric	Athira Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$72.05M	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-1.83	787.27	273.28	25.38
Price / Sales	N/A	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	2.15	12.33	12.89	6.14
Net Income	-$105.61M	$2.82B	$3.47B	$349.01M
7 Day Performance	-3.02%	2.60%	0.61%	-0.27%
1 Month Performance	0.52%	6.96%	5.73%	0.68%
1 Year Performance	N/A	9.48%	25.37%	14.84%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LONA Athira Pharma	2.9387 of 5 stars	$7.70 +0.4%	$17.33 +125.1%	N/A	$72.05M	N/A	N/A	40
TTRX Turn Therapeutics	1.1144 of 5 stars	$9.73 +0.5%	$8.00 -17.8%	N/A	$288.35M	N/A	N/A	2
NMRA Neumora Therapeutics	1.9604 of 5 stars	$1.50 -1.6%	$6.57 +338.1%	-22.9%	$286.54M	N/A	N/A	108
ZNTL Zentalis Pharmaceuticals	2.7551 of 5 stars	$3.88 +3.2%	$6.75 +74.0%	+140.4%	$269.49M	$67.43M	N/A	160	Positive News
ACB Aurora Cannabis	1.5361 of 5 stars	$4.01 +1.8%	N/A	-20.8%	$255.48M	$247.82M	N/A	1,028

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (LONA) Competitors

LONA vs. TTRX, NMRA, ZNTL, ACB, and NERV

How does Athira Pharma compare to Turn Therapeutics?

Summary

How does Athira Pharma compare to Neumora Therapeutics?

Summary

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Summary

How does Athira Pharma compare to Aurora Cannabis?

Summary

How does Athira Pharma compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (LONA) Competitors

LONA vs. TTRX, NMRA, ZNTL, ACB, and NERV

How does Athira Pharma compare to Turn Therapeutics?

Which has better valuation and earnings, LONA or TTRX?

Do insiders and institutionals hold more shares of LONA or TTRX?

Does the media prefer LONA or TTRX?

Do analysts rate LONA or TTRX?

Is LONA or TTRX more profitable?

Summary

How does Athira Pharma compare to Neumora Therapeutics?

Which has preferable earnings and valuation, LONA or NMRA?

Which has more risk and volatility, LONA or NMRA?

Do analysts rate LONA or NMRA?

Does the media refer more to LONA or NMRA?

Is LONA or NMRA more profitable?

Do institutionals and insiders believe in LONA or NMRA?

Summary

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Is LONA or ZNTL more profitable?

Which has stronger valuation and earnings, LONA or ZNTL?

Do insiders & institutionals have more ownership in LONA or ZNTL?

Which has more risk and volatility, LONA or ZNTL?

Do analysts prefer LONA or ZNTL?

Does the media refer more to LONA or ZNTL?

Summary

How does Athira Pharma compare to Aurora Cannabis?

Do analysts prefer LONA or ACB?

Which has more risk & volatility, LONA or ACB?

Do insiders and institutionals hold more shares of LONA or ACB?

Does the media refer more to LONA or ACB?

Is LONA or ACB more profitable?

Which has higher valuation and earnings, LONA or ACB?

Summary

How does Athira Pharma compare to Minerva Neurosciences?

Do analysts rate LONA or NERV?

Do insiders & institutionals hold more shares of LONA or NERV?

Does the media favor LONA or NERV?

Which has more risk and volatility, LONA or NERV?

Which has better valuation and earnings, LONA or NERV?

Is LONA or NERV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools